PARKINSON'S DISEASE NEWS
24th October 2009 - New research
GAUCHER'S DISEASE AND PARKINSON'S DISEASE
New England Journal of Medicine
 361 (17) : 1651-1661
(Sidransky et al)
It is named after the French doctor Philippe Gaucher, who originally described it. For more information go to Gaucher's Disease. A lot of people are carriers for Gaucher's Disease without realising it. Around 1 in 100 people are a carrier for Gaucher's Disease. In Ashkenazi Jews as many as 1 in 15 are a carrier. Those people that had Gaucher's Disease and Parkinson's Disease developed Parkinson's Disease at an earlier age, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. Although it is known what causes Gaucher's Disease, it is not known how that can also cause the symptoms of Parkinson's Disease. In order to refer to this article on its own click here.
23rd October 2009 - New book
DEEP WITHIN THE BRAIN : LIVING WITH PARKINSON'S DISEASE
Helmut Dubiel, Hubert H.
19th October 2009 - New research
THE EFFECT OF MAO
INHIBITORS ON PARKINSON'S DISEASE
Those people taking MAO-B inhibitors were far more likely to require additional treatments than those taking L-dopa or dopamine agonists. MAO-B inhibitors were sufficient on their own in very few people. MAO-B inhibitors caused far fewer motor fluctuations than L-dopa, but a bit more than dopamine agonists. Withdrawals due to adverse events were far less common with MAO-B inhibitors than with dopamine agonists. The authors concluded that MAO-B inhibitors are one option for the early treatment of Parkinson's Disease, but that they have weaker effects than L-dopa and dopamine agonists. In order to refer to this article on its own click here.
15th October 2009 - News release
THE EFFECT OF COGANE ON PARKINSON'S DISEASE
However, GDNF deficiency has never been shown to be the cause of Parkinson's Disease. GDNF was found to be ineffective in clinical trials in humans. Although Phytopharm claim that Cogane can reverse the effects of Parkinson's Disease, Cogane has never reversed the effects of Parkinson's Disease in anyone. The efficacy study was only carried out on Macaque monkeys. Macaque monkeys do not have Parkinson's Disease. What is described as Parkinson's Disease in monkeys is usually only drug induced. In order to refer to this article on its own click here.
14th October 2009 - News report
AGENT ORANGE ACCEPTED
AS A CAUSE OF PARKINSON'S DISEASE
Their acknowledgement of an association is based entirely on the "Veterans and Agent Orange Update 2008", which can be read here. Although the report claims to "link" Agent Orange to Parkinson's Disease, it fails to provide any evidence showing that Agent Orange had caused Parkinson's Disease. There have been over 300 published studies on the effects of Agent Orange, yet none of them have shown that Agent Orange has caused Parkinson's Disease. Toxic exposure can not begin to have an effect on Parkinson's Disease years or decades after toxic exposure as is often claimed. It can occur in almost anyone without toxicity being the cause. In order to refer to this article on its own click here.
11th October 2009 - New research
DUAL LAYER L-DOPA FOR PARKINSON'S DISEASE
Clinical Neuropharmacology  32 (4) : 189-192 (Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.) Complete abstract
IPX054, which is a form of L-dopa, in which there are two layers, has been shown to be slightly more effective than conventional forms of L-dopa, despite only having to be taken twice a day instead of throughout the day. L-dopa usually comes in two different formats : either the immediate release version, which satisfies the immediate need for L-dopa, or the controlled release version, which avoids the excessive effects of L-dopa by spreading out the effect over time. IPX054 combines the two types of L-dopa, immediate release and controlled release, in one tablet, in two different layers, aiming to provide the benefits of both formats. In clinical practice, this ease of administration may offer improved treatment compliance and effectiveness. In order to refer to this article on its own click here.
7th October 2009 - News release
MAGNETIC THERAPY FOR PARKINSON'S DISEASE
Pico-Tesla claim to have shown “significant improvement over placebo” in reducing Parkinson’s disease symptoms using their magnetic therapy Magneceutical, that persisted for up to two months after treatment without side effects. The level of improvement was not disclosed. For more information read the News release.
involves the use of an extremely low-level electromagnetic field applied by a
specially designed device, the Resonator, along with proprietary therapeutic
protocols, intended to improve a number of the signs and symptoms of Parkinson’s
and other neurological disorders. Helmholtz coils immerse the entire patient in
a low strength electromagnetic field. The strength and duration of the magnetic
fields are regulated by Pico-Tesla via the internet. The mechanism of action of
magnetic therapy is not known. For more information concerning the method
used go to
In order to refer to this article
on its own
5th October 2009 - New research
L-SULPIRIDE AS A CAUSE OF
So the aim of this study was to investigate the clinical characteristics of patients with L-Sulpiride-induced movement disorders (LIM). The most common L-Sulpiride-induced movement disorder was Parkinsonism making up over 90% of cases, followed by tardive dyskinesia with about 10% of cases, and isolated tremor affecting only 3% of cases. The symptoms are often severe, and L-Sulpiride-induced movement disorders still persisted even after withdrawal of L-Sulpiride in nearly half of those patients with L-Sulpiride induced Parkinsonism. In order to refer to this article on its own click here.
1st October 2009 - New research
THE EFFECT OF RASAGILINE ON
The clinical trial involved over a thousand patients. In early-start treatment with Rasagiline at a dose of 1 mg per day, there was actually a worsening of Parkinson's Disease symptoms throughout the clinical trial. As time progressed during the clinical trial, the effect of 1mg Rasagiline was found to be no different from those people that had taken Rasagiline for only half of the time. The use of 2mg Rasagiline per day was also shown to be no better than the use of 1mg or delaying the use of Rasagiline. In order to refer to this article on its own click here.